Life-Saving MCC3000 Technology

 

Every two minutes in the United States, a person’s heart stops beating. Standard therapies include CPR, defibrillation and medical therapies, which may not be effective in resuscitating these patients. Roughly 80 percent of patients suffering cardiac arrest in a hospital do not survive to discharge despite the best efforts of trained medical personnel.

 

MyoCardioCare was created to commercialize an innovative heart pump that has the potential to significantly improve these results. The MCC3000 device consists of a single-use, pneumatically-powered, flexible, polymer cup that rhythmically compresses and expands the heart, restoring and maintaining circulation. Investments in this technology to date have supported over 650 animal studies, as well as demonstration of initial effectiveness in humans. At Duke University Medical Center, five patients required emergency cardiac support and an earlier version of the MyoCardioCare technology was inserted and successfully used. These devices remained inside the patients and supported them from two days to as long as three months.

​

Unlike other devices, the MCC3000 has the ability to support both ventricles of a patient’s heart. It is capable of optimizing cardiac output, providing oxygenated blood to the body. It can be used to provide a patient’s heart the time to heal. If healing is not possible, it can be used as a bridge to other methods of treatment.

 

Advantages of the MCC3000

• The MCC3000 will provide the only acute circulatory support product targeted to be used with in-hospital cardiac arrest patients. The MCC3000 can be installed in under five minutes, providing immediate resuscitation.

• The cup is inserted through a surgical incision between the ribs. It does not involve further incisions into the heart or major blood vessels.

• The MCC3000 supports both ventricles of the heart (right and left), providing increased perfusion of oxygenated blood to the body.

• The MCC3000 enables the heart to eject and fill with blood (systole and diastole). This (diastolic) support is vital because it helps optimize the filling of both ventricles which, in turn, optimizes cardiac output and blood flow.

• The device does not contact circulating blood. This eliminates or significantly reduces the known problems associated with blood contacting devices.

• The cup can be produced in various sizes, permitting its use on a wide range of patients.

• The MCC3000 can be inserted by general surgeons, as well as cardiothoracic surgeons. Once it is commercialized, the device will be available for use at community hospitals, not just specialized cardiac care centers. This will permit the technology to help more patients in cardiac arrest.

​